[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB201602802D0 - Method of treatment - Google Patents

Method of treatment

Info

Publication number
GB201602802D0
GB201602802D0 GBGB1602802.9A GB201602802A GB201602802D0 GB 201602802 D0 GB201602802 D0 GB 201602802D0 GB 201602802 A GB201602802 A GB 201602802A GB 201602802 D0 GB201602802 D0 GB 201602802D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1602802.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Priority to GBGB1602802.9A priority Critical patent/GB201602802D0/en
Publication of GB201602802D0 publication Critical patent/GB201602802D0/en
Priority to PCT/EP2017/053714 priority patent/WO2017140903A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1602802.9A 2016-02-17 2016-02-17 Method of treatment Ceased GB201602802D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1602802.9A GB201602802D0 (en) 2016-02-17 2016-02-17 Method of treatment
PCT/EP2017/053714 WO2017140903A1 (en) 2016-02-17 2017-02-17 Method of treatment of complement mediated neurodevelopmental disorder secondary to zika virus infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1602802.9A GB201602802D0 (en) 2016-02-17 2016-02-17 Method of treatment

Publications (1)

Publication Number Publication Date
GB201602802D0 true GB201602802D0 (en) 2016-03-30

Family

ID=55697811

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1602802.9A Ceased GB201602802D0 (en) 2016-02-17 2016-02-17 Method of treatment

Country Status (2)

Country Link
GB (1) GB201602802D0 (en)
WO (1) WO2017140903A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116769024A (en) 2016-06-14 2023-09-19 瑞泽恩制药公司 anti-C5 antibodies and uses thereof
MA51147A (en) 2017-12-13 2021-03-24 Regeneron Pharma ANTI-C5 ANTIBODY ASSOCIATIONS AND ASSOCIATED USES
WO2021058117A1 (en) 2019-09-27 2021-04-01 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526083C (en) 2003-06-02 2017-01-17 Evolutec Limited Complement inhibitors
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EP2061501B1 (en) 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
PL2521562T3 (en) 2010-01-08 2020-04-30 Volution Immuno Pharmaceuticals Sa Ev576 for use in the treatment of viral infections of the respiratory tract
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment

Also Published As

Publication number Publication date
WO2017140903A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
GB201701673D0 (en) Methods of well treatment
HK1252568A1 (en) A method of treatment
HK1248552A1 (en) Method of treatment with tradipitant
ZA201903873B (en) Methods of treating cochlear synaptopathy
GB201410116D0 (en) Method of treatment
EP3684342C0 (en) Method of treatment
HK1247818A1 (en) Method of treating diseases
GB201706406D0 (en) Method of treatment
IL261850B (en) Methods of vitamin d treatment
IL253028A0 (en) Method of treatment
GB201815588D0 (en) Method of treatment
GB201416832D0 (en) Methods of treatment
EP3490547A4 (en) Method of treatment
GB201602802D0 (en) Method of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
HK1250243A1 (en) A method of treatment
HK1243937A1 (en) Methods of treating diseases
GB2558216B (en) Method of heat treatment
GB201512139D0 (en) Methods of treatment
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment
GB201709554D0 (en) Method of treatment
GB201706642D0 (en) Method of treatment
GB201706452D0 (en) Method of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)